Gastric adenocarcinoma

This clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…

Researchers are testing an experimental drug called MRG003 in adults with advanced gastric or gastroesophageal junction cancer that has spread or cannot be removed by surgery. The trial enrolls people whose tumors test positive for EGFR and negative for HER2, a combination that l…

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…

This phase 2 trial is testing whether toripalimab, an immunotherapy drug, can shrink tumors in people with advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments. Participants receive toripalimab every three weeks. The main goal…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This study tested a combination of chemotherapy drugs for people with stomach cancer that has spread inside the belly. The treatment involved giving one drug directly into the abdomen and through a vein, plus a second drug taken by mouth. The goal was to see if this approach coul…

This early-stage trial tested a new drug called AUR103 calcium, given together with standard treatments (trastuzumab and chemotherapy), for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study aimed to find a safe dose and check if the combina…

This study aimed to compare two different ways of giving chemotherapy (FLOT) to people with stomach or gastroesophageal junction cancer. One group received all chemotherapy before surgery, while the other received some before and some after surgery. The study was stopped early af…

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…

This study tested whether adding surgery to chemotherapy helps people with stage IV stomach cancer that has spread to only one other area. The goal was to see if surgery could improve survival and quality of life. However, the trial was stopped early after enrolling only 6 partic…

This phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This early-phase study tested an experimental drug called AMG 199 in adults with advanced stomach, gastroesophageal junction, colorectal, or pancreatic cancers that have a specific protein (MUC17). The main goals were to check safety and find the best dose. The study was stopped …

This study tested a new drug called DKN-01 combined with tislelizumab and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that could not be removed by surgery. The trial enrolled 247 adults who had not received prior treatment or whose cancer had…

This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…

This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…

This study aimed to find genetic and lifestyle factors that increase stomach cancer risk in a mostly Hispanic population in South Texas. Researchers compared DNA from cancer tissue and saliva, and surveyed patients about diet, health history, and exposures. The goal was to unders…